微小RNA与肺癌

国际肿瘤学杂志››2015,Vol. 42››Issue (2): 144-146.doi:10.3760/cma.j.issn.1673-422X.2015.02.017

向敏,朱玲,陈艳,刘馨,王熙才

650118 昆明医科大学第三附属医院肿瘤研究所；云南省肿瘤医院肿瘤研究所

出版日期:2015-02-08发布日期:2015-02-02
通讯作者:Wang Xicai E-mail:wangxc2005323@126.com
基金资助:

国家自然科学基金（81460358)；云南省卫生科技基金（2012WS041）;云南省孔祥复院士基金

microRNAs and lung cancer

Xiang Min, Zhu Ling, Chen Yan, Liu Xin, Wang Xicai

Cancer Institute, Third Affiliated Hospital of Kunming Medical College, Cancer Institute of Yunnan Tumor Hospital, Kunming 650118, China

Online:2015-02-08Published:2015-02-02
Contact:王熙才 E-mail:wangxc2005323@126.com

摘要/Abstract

摘要：微小RNA（miRNA）是短的非编码蛋白质的RNA，其在细胞增殖、分化、凋亡以及致癌和抗癌信号激活中起重要作用。研究表明，miRNA的异常表达与肺癌的发生、组织学类型、诊断、治疗和预后密切相关，其可能成为肺癌最有潜力和前途的治疗靶点。

向敏,朱玲,陈艳,刘馨,王熙才. 微小RNA与肺癌[J]. 国际肿瘤学杂志, 2015, 42(2): 144-146.

Xiang Min, Zhu Ling, Chen Yan, Liu Xin, Wang Xicai. microRNAs and lung cancer[J]. Journal of International Oncology, 2015, 42(2): 144-146.

［1］ Crowell RE, Goetz T, Wiggins C, et al. Regional disparities in treatment and survival of early stage nonsmall cell lung cancer［J］. Ethn Dis, 2007, 17(2): 358-364. ［2］ Lee RC, Feinbaum RL, Ambros V. The C.elegans heterochronic gene lin4 encodes small RNAs with antisense complementarity to lin14［J］. Cell, 1993, 75(5): 843-854. ［3］ Farazi TA, Spitzer JI, Morozov P, et al. miRNAs in human cancer［J］. J Pathol, 2011, 223(2): 102-115. ［4］ KsiazekWiniarek DJ, Kacperska MJ, Glabinski A. MicroRNAs as novel regulators of neuroinflammation［J］. Mediators Inflamm, 2013, 2013: 172351. ［5］ Taft RJ, Simons C, Nahkuri S, et al. Nuclearlocalized tiny RNAs are associated with transcription initiation and splice sitesin metazoans［J］. Nat Struct Mol Biol, 2010, 17(8): 1030-1034. ［6］ Deng G, Sui G. Noncoding RNA in oncogenesis: a new era of identifying keyplayers［J］. Int J Mol Sci, 2013, 14(9): 18319-18349. ［7］ Peng Y, Dai Y, Hitchcock C, et al. Insulin growth factor signaling is regulated by microRNA486, an underexpressed microRNA in lung cancer［J］. Proc Natl Acad Sci USA, 2013, 110(37): 15043-15048. ［8］ Liu ZL, Wang H, Liu J, et al. MicroRNA21 (miR21) expression promotes growth, metastasis, and chemo or radioresistance in nonsmall cell lung cancer cells by targeting PTEN［J］. Mol Cell Biochem, 2013, 372(12): 35-45. ［9］ Gao W, Yu Y, Cao H, et al. Deregulated expression of miR21, miR143 and miR181a in non small cell lung cancer is related to clinicopathologic characteristics or patient prognosis［J］. Biomed Pharmacother, 2010, 64 (6): 399-408. ［10］ Yu L, Todd NW, Xing L, et al. Early detection of lung adenocarcinoma in sputum by a panel of microRNA markers［J］. Int J Cancer, 2010, 127(12): 2870-2878. ［11］ Wu X, Liu T, Fang O, et al. miR194 suppresses metastasis of nonsmall cell lung cancer through regulating expression of BMP1 and p27(kip1)［J］. Oncogene, 2014, 33(12): 1506-1514. ［12］ Gibbons DL, Lin W, Creighton CJ, et al. Contextual extracellular cues promote tumor cell EMT and metastasis by regulating miR200 family expression［J］. Genes Dev, 2009, 23(18): 21402151. ［13］ Zhao B, Han H, Chen J, et al. MicroRNA let7c inhibits migration and invasion of human nonsmall cell lung cancer by targeting ITGB3 and MAP4K3［J］. Cancer Lett, 2014, 342(1): 43-51. ［14］ Arora S, Ranade AR, Tran NL, et al. MicroRNA328 is associated with (nonsmall) cell lung cancer (NSCLC) brain metastasis and mediates NSCLC migration［J］. Int J Cancer, 2011, 129(11): 2621-2631. ［15］ Liu YJ, Lin YF, Chen YF, et al. MicroRNA449a enhances radiosensitivity in CL10 lung adenocarcinoma cells［J］. PLoS One, 2013, 8(4): e62383. ［16］ Grosso S, Doyen J, Parks SK, et al. MiR210 promotes a hypoxic phenotype and increases radioresistance in human lung cancer cell lines［J］. Cell Death Dis, 2013, 4: e544. ［17］ Qiu T, Zhou L, Wang T, et al. miR503 regulates the resistance of nonsmall cell lung cancer cells to cisplatin by targeting Bcl2［J］. Int J Mol Med, 2013, 32(3): 593-598. ［18］ Zhu X, Li H, Long L, et al. miR126 enhances the sensitivity of nonsmall cell lung cancer cells to anticancer agents by targeting vascular endothelial growth factor A［J］. Acta Biochim Biophys Sin (Shanghai), 2012, 44(6): 519-526. ［19］ Franchina T, Amodeo V, Bronte G, et al. Circulating miR22, miR24 and miR34a as novel predictive biomarkers to pemetrexedbased chemotherapy in advanced nonsmall cell lung cancer［J］. J Cell Physiol, 2014, 229(1): 97-99. ［20］ Chen G, Umelo IA, Lv S, et al. miR146a inhibits cell growth, cell migration and induces apoptosis in nonsmall cell lung cancer cells［J］. PLoS One, 2013, 8(3): e60317. ［21］ Markou A, Tsaroucha EG, Kaklamanis L, et al. Prognostic value of mature microRNA21 and microRNA205 overexpression in nonsmall cell lung cancer by quantitative realtime RTPCR［J］. Clin Chem, 2008, 54(10): 1696-1704.

[1]	刘娜, 寇介丽, 杨枫, 刘桃桃, 李丹萍, 韩君蕊, 杨立洲.血清miR-106b-5p、miR-760联合低剂量螺旋CT诊断早期肺癌的临床价值[J]. 国际肿瘤学杂志, 2024, 51(6): 321-325.
[2]	王丽, 刘志华, 杨伟洪, 蒋凤莲, 李全泳, 宋浩杰, 鞠文东.ROS1突变肺腺鳞癌合并脑梗死为主要表现的Trousseau综合征1例[J]. 国际肿瘤学杂志, 2024, 51(6): 382-384.
[3]	龚艳, 陈洪雷.微RNA调控卵巢癌顺铂耐药的机制研究进展[J]. 国际肿瘤学杂志, 2024, 51(3): 186-190.
[4]	贺嘉慧, 胡钦勇.基于GBD数据的中国和美国肺癌发病和死亡趋势及危险因素对比分析[J]. 国际肿瘤学杂志, 2024, 51(1): 29-36.
[5]	全祯豪, 徐飞鹏, 黄哲, 黄先进, 陈日红, 孙开裕, 胡旭, 林琳.沉默lncRNA FTX通过miR-22-3p/NLRP3炎症体通路抑制胃癌细胞增殖[J]. 国际肿瘤学杂志, 2023, 50(4): 202-207.
[6]	李雄安, 颜艳艳.丙戊酸镁用于治疗继发癫痫的晚期肺癌脑转移患者1例报道[J]. 国际肿瘤学杂志, 2023, 50(3): 191-192.
[7]	左小平, 刘晓川, 吴西强, 李周, 夏天, 刘国凤.老年早期肺癌患者经胸腔镜肺切除术后心律失常发生的危险因素及预测模型构建[J]. 国际肿瘤学杂志, 2023, 50(12): 711-716.
[8]	陈郁, 许华, 刘海, 陈士新.基于CT影像学特征的恶性肺纯磨玻璃结节患者病理分型预测模型构建[J]. 国际肿瘤学杂志, 2023, 50(11): 655-660.
[9]	张万芳, 王尤, 苏晶, 陈刚, 周福祥.肺原发尤文肉瘤/原始神经外胚层瘤1例[J]. 国际肿瘤学杂志, 2023, 50(1): 62-64.
[10]	杨莎, 杨晓华, 王苏华, 薛晓燕, 徐俊.老年肺癌胸腔镜手术后下肢深静脉血栓的危险因素分析及预测模型的建立和验证[J]. 国际肿瘤学杂志, 2022, 49(9): 532-536.
[11]	王津, 张耀圣, 孙婷婷, 王丹, 胡乃东.以前胸壁聚集性多发蕈状肿物为表现的肺腺鳞状细胞癌皮肤转移1例[J]. 国际肿瘤学杂志, 2022, 49(9): 575-576.
[12]	陈煌婧, 朱鹏飞, 张晴, 陈桂芳, 杨春林, 何英.超声造影和CT引导下经皮穿刺活检在周围型肺肿块诊断中临床价值的比较[J]. 国际肿瘤学杂志, 2022, 49(8): 459-463.
[13]	蔡刚祥, 李境, 许斌.肺癌新辅助免疫治疗研究进展[J]. 国际肿瘤学杂志, 2022, 49(6): 366-370.
[14]	韩丛丛, 付帅, 谢超, 张建军, 张秋景, 祝情情, 刘杰.吉非替尼、培美曲塞和贝伐珠单抗一线治疗EGFR突变晚期肺腺癌的有效性和安全性[J]. 国际肿瘤学杂志, 2022, 49(6): 376-379.
[15]	王永洪, 何弢, 李星, 罗启余, 王乔羽.信迪利单抗致晚期鳞状细胞肺癌患者致死性中毒性表皮坏死松解症1例[J]. 国际肿瘤学杂志, 2022, 49(6): 380-382.